These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16860258)

  • 1. Tolerability of atorvastatin in a population aged > or =65 years: a retrospective pooled analysis of results from fifty randomized clinical trials.
    Hey-Hadavi JH; Kuntze E; Luo D; Silverman P; Pittman D; Lepetri B
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):112-22. PubMed ID: 16860258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients.
    Newman C; Tsai J; Szarek M; Luo D; Gibson E
    Am J Cardiol; 2006 Jan; 97(1):61-7. PubMed ID: 16377285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients.
    Newman CB; Palmer G; Silbershatz H; Szarek M
    Am J Cardiol; 2003 Sep; 92(6):670-6. PubMed ID: 12972104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials.
    Soni P; Shell B; Cawkwell G; Li C; Ma H
    Curr Med Res Opin; 2009 Aug; 25(8):1841-51. PubMed ID: 19530981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
    Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
    Goldberg RB; Guyton JR; Mazzone T; Weinstock RS; Polis A; Edwards P; Tomassini JE; Tershakovec AM
    Mayo Clin Proc; 2006 Dec; 81(12):1579-88. PubMed ID: 17165637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.
    Marcinak JF; Munsaka MS; Watkins PB; Ohira T; Smith N
    Drug Saf; 2018 Jun; 41(6):625-640. PubMed ID: 29492878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
    Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
    J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
    Ballantyne CM; Houri J; Notarbartolo A; Melani L; Lipka LJ; Suresh R; Sun S; LeBeaut AP; Sager PT; Veltri EP;
    Circulation; 2003 May; 107(19):2409-15. PubMed ID: 12719279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS).
    Ballantyne CM; Blazing MA; Hunninghake DB; Davidson MH; Yuan Z; DeLucca P; Ramsey KE; Hustad CM; Palmisano J
    Am Heart J; 2003 Nov; 146(5):862-9. PubMed ID: 14597936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS).
    Newman CB; Szarek M; Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Demicco DA; Auster S; Fuller JH;
    Diab Vasc Dis Res; 2008 Sep; 5(3):177-83. PubMed ID: 18777490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study.
    Farsang C; Athyros V; Gaw A;
    Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.
    Masana L; Mata P; Gagné C; Sirah W; Cho M; Johnson-Levonas AO; Meehan A; Troxell JK; Gumbiner B;
    Clin Ther; 2005 Feb; 27(2):174-84. PubMed ID: 15811480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Atorvastatin in the treatment of patients with hereditary hypercholesterolemia].
    Susekov AV; Balakhonova TV; Pogorelova OA; Aligisheeva ZA; Titov VN; At'kov OIu; Kukharchuk VV
    Kardiologiia; 2003; 43(8):36-9. PubMed ID: 14593381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin.
    Rogers SL; Magliano DJ; Levison DB; Webb K; Clarke PJ; Grobler MP; Liew D
    Clin Ther; 2007 Feb; 29(2):242-52. PubMed ID: 17472817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.